Douglas Lane & Associates LLC Reduces Holdings in CVS Health Corporation $CVS

Key Points

• Douglas Lane & Associates cut its CVS Health stake by 15.5% in the third quarter, selling 43,924 shares and retaining 240,188 shares valued at approximately $20.6 million. Institutional investors collectively own about 80.66% of CVS.
• CVS reported quarterly earnings of $2.58 per share, well above the $1.87 consensus estimate, while revenue rose 7.3% year over year to $106.1 billion. The company maintained fiscal 2026 EPS guidance of $7.90–$8.10.
• Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $107.24 versus a recent share price of $87.01. CVS also declared a quarterly dividend of $0.665 per share, representing a 3.1% annualized yield.

Douglas Lane & Associates LLC lowered its holdings in CVS Health Corporation (NYSE:CVS - Free Report) by 15.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 240,188 shares of the pharmacy operator's stock after selling 43,924 shares during the period. Douglas Lane & Associates LLC's holdings in CVS Health were worth $20,582,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in CVS. Stableford Capital II LLC purchased a new stake in CVS Health during the third quarter worth about $687,000. Mn Services Vermogensbeheer B.V. grew its position in shares of CVS Health by 1.3% during the 3rd quarter. Mn Services Vermogensbeheer B.V. now owns 375,568 shares of the pharmacy operator's stock valued at $32,182,000 after acquiring an additional 4,900 shares during the period. Farther Finance Advisors LLC increased its stake in shares of CVS Health by 30.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 54,244 shares of the pharmacy operator's stock worth $4,648,000 after purchasing an additional 12,718 shares during the last quarter. CoreCap Advisors LLC raised its holdings in shares of CVS Health by 50.6% in the 3rd quarter. CoreCap Advisors LLC now owns 5,242 shares of the pharmacy operator's stock worth $449,000 after purchasing an additional 1,761 shares during the period. Finally, Artemis Investment Management LLP lifted its stake in CVS Health by 65.6% in the third quarter. Artemis Investment Management LLP now owns 50,481 shares of the pharmacy operator's stock valued at $4,326,000 after purchasing an additional 20,000 shares during the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Long-term drug-distribution agreements extended: CVS renewed pharmaceutical distribution contracts with Cardinal Health and McKesson through 2032, supporting supply continuity for its retail pharmacies and other dispensing channels. What Does CVS Health Gain From Extending Its Drug Distribution Deals to 2032?
• Positive Sentiment: Aetna still reports broad four-star coverage: More than 69% of Aetna Medicare Advantage members are enrolled in plans rated four stars or higher for 2027. CVS says the results reflect solid clinical quality and member experience, which could help support enrollment and reimbursement in much of the business. Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience
• Neutral Sentiment: Pharmacy-focused store opens in Boston: CVS launched its first pharmacy-only location in the Boston area, emphasizing prescriptions, vaccinations and pharmacist-led care. The smaller format may improve access and lower operating requirements, although the immediate financial impact is unclear. CVS Opens First Pharmacy-Focused Location in Boston Area
• Negative Sentiment: Medicare Advantage ratings are the key concern: TD Cowen estimates the share of CVS’s Medicare Advantage members in plans rated at least 4.5 stars could fall to about 35% from 63%. Analysts warn that the setback could pressure bonus payments, margins and Aetna’s competitive position, particularly as Humana benefits from improved ratings. TD Cowen Warns of Bottom-Line Pressure Amid Star Ratings Setback
• Negative Sentiment: Investors remain focused on healthcare profitability: Rising healthcare spending does not necessarily translate into stronger earnings, as medical costs, government reimbursement and regulation can limit insurers’ margins. That backdrop amplifies concerns about CVS’s Medicare Advantage performance. Seniors Face an 18% Drop in Highly Rated Medicare Advantage Plans

Wall Street Analysts Forecast Growth

CVS has been the subject of a number of recent research reports. Robert W. Baird set a $107.00 target price on CVS Health in a research report on Thursday, August 6th. UBS Group reiterated a "buy" rating on shares of CVS Health in a research note on Tuesday, September 22nd. BMO Capital Markets set a $112.00 price objective on CVS Health in a report on Wednesday, September 9th. JPMorgan Chase & Co. upped their price objective on shares of CVS Health from $111.00 to $118.00 and gave the company an "overweight" rating in a report on Wednesday, August 12th. Finally, Sanford C. Bernstein reiterated an "outperform" rating and set a $112.00 target price on shares of CVS Health in a research report on Wednesday, September 9th. Twenty-one analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, CVS Health presently has an average rating of "Moderate Buy" and a consensus price target of $107.24.

CVS Health Price Performance

NYSE CVS traded down $0.79 during trading hours on Friday, hitting $87.01. The company had a trading volume of 5,590,040 shares, compared to its average volume of 8,288,887. CVS Health Corporation has a 52 week low of $69.51 and a 52 week high of $110.68. The firm has a 50 day simple moving average of $93.10 and a 200 day simple moving average of $92.41. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. The firm has a market capitalization of $111.28 billion, a price-to-earnings ratio of 23.03, a PEG ratio of 0.82 and a beta of 0.60.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.71. The firm had revenue of $106.10 billion for the quarter, compared to analysts' expectations of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The company's revenue was up 7.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Equities research analysts expect that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Thursday, October 22nd will be given a $0.6650 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Thursday, October 22nd. CVS Health's dividend payout ratio (DPR) is 70.37%.

About CVS Health

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company's major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.